Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BTZ043 in Healthy Volunteers
NCT03590600Phase 1Completed
- Start
- Jun 2018
- Primary completion
- Aug 2018
- Modality
- Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BTZ-043 in Tuberculosis (TB) (10 cohorts). Primary endpoints: Treatment-related adverse events concerning ECG, Treatment-related adverse events concerning safety laboratory and 2 more. Started Jun 2018; status: completed.
02
Drugs
BTZ-043
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03590600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03590600.